Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$472.00 USD
+0.56 (0.12%)
Updated Aug 15, 2024 04:00 PM ET
Pre-Market: $471.33 -0.67 (-0.14%) 8:24 AM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$472.00 USD
+0.56 (0.12%)
Updated Aug 15, 2024 04:00 PM ET
Pre-Market: $471.33 -0.67 (-0.14%) 8:24 AM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Pfizer (PFE) to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $367.66, denoting a +1.6% change from the preceding trading day.
Intellia (NTLA) Focuses on Developing Gene-Editing Therapies
by Zacks Equity Research
Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage development and progressing well.
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.
Intellia's (NTLA) IND for Gene-Editing Therapy Gets FDA Clearance
by Zacks Equity Research
Intellia (NTLA) gets FDA nod to begin a phase III study on its gene editing candidate, NTLA-2001 to treat transthyretin amyloidosis with cardiomyopathy. The study is set to begin by 2023-end.
GILD or VRTX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GILD vs. VRTX: Which Stock Is the Better Value Option?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
5 Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Zacks Equity Research
Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.
Why Vertex (VRTX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vertex Pharmaceuticals (VRTX) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $374, denoting a +0.81% change from the preceding trading day.
Here's Why You May Invest in CRISPR Therapeutics (CRSP) Stock
by Zacks Equity Research
Here we discuss some reasons why investing in CRISPR Therapeutics (CRSP) stock now may turn out to be a more prudent move than ever.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
BEAM Focuses on Developing Gene Drug for Growth
by Zacks Equity Research
While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $355.20, indicating a -1.5% shift from the previous trading day.
Zacks Investment Ideas feature highlights: Applied Industrial, Applied Materials and Vertex Pharmaceuticals
by Zacks Equity Research
Applied Industrial, Applied Materials and Vertex Pharmaceuticals have been highlighted in this Investment Ideas article.
3 Top Ranked Stocks with Superior Free Cash Flow Yield
by Ethan Feller
In this article, we'll introduce you to three standout stocks with impressive FCF yields, remarkable historical returns, and top Zacks Ranks
Top Analyst Reports for Berkshire Hathaway, Broadcom & Comcast
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Broadcom Inc. (AVGO) and Comcast Corporation (CMCSA).
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $347.83, marking a +0.03% move from the previous day.
Revvity's (RVTY) New Launch to Widen Access to Editing Technology
by Zacks Equity Research
Revvity's (RVTY) latest offering is likely to improve access to new-generation editing technology and bridge both preclinical and clinical discoveries with the same technology platform.
Is It Worth Investing in Vertex (VRTX) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Vertex (VRTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $350.67 in the latest trading session, marking a +0.33% move from the prior day.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $358.26, marking a +1.78% move from the previous day.
Vertex (VRTX) Gets Positive CHMP Opinion for Kaftrio Expanded Use
by Zacks Equity Research
Vertex's (VRTX) Kaftrio gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use to treat younger age groups of two to five years old with cystic fibrosis.